ILLUMINA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.3 USD | +1.02% |
|
+4.13% | -12.18% |
| 22/04 | Bernstein Adjusts Price Target on Illumina to $129 From $150 | MT |
| 22/04 | Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept | MT |
| Sales 2024 * | 4.51B 376B | Sales 2025 * | 4.96B 413B | Capitalization | 19.47B 1,624B |
|---|---|---|---|---|---|
| Net income 2024 * | -137M -11.42B | Net income 2025 * | 286M 23.85B | EV / Sales 2024 * | 4.32 x |
| Net Debt 2024 * | 23.8M 1.98B | Net cash position 2025 * | 770M 64.22B | EV / Sales 2025 * | 3.77 x |
| P/E ratio 2024 * |
-174
x | P/E ratio 2025 * |
59.6
x | Employees | 10,615 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Illumina, Inc.
More recommendations
More press releases
More news
| 1 day | +1.02% | ||
| 1 week | +4.13% | ||
| Current month | -10.95% | ||
| 1 month | -8.61% | ||
| 3 months | -13.05% | ||
| 6 months | +9.54% | ||
| Current year | -12.18% |
1 week
116.91
125.70
1 month
115.73140.07
Current year
115.73148.19
1 year
89.00213.91
3 years
89.00526.00
5 years
89.00555.77
10 years
89.00555.77
| Managers | Title | Age | Since |
|---|---|---|---|
Jacob Thaysen
CEO | Chief Executive Officer | 49 | 25/23/25 |
Steven Barnard
CTO | Chief Tech/Sci/R&D Officer | - | 01/98/01 |
Carissa Rollins
CTO | Chief Tech/Sci/R&D Officer | 54 | 14/22/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 29/12/29 |
| Chairman | 60 | 02/23/02 | |
Caroline Dorsa
BRD | Director/Board Member | 64 | 27/17/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.11% | 2 M€ | -.--% | ||
| 3.62% | 1 M€ | -5.79% | - | |
| 3.11% | 0 M€ | 0.00% | - | |
| 3.03% | 0 M€ | 0.00% | - | |
| 1.77% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 122.3 | +1.02% | 829,331 |
| 25/24/25 | 121 | -1.48% | 962,789 |
| 24/24/24 | 122.9 | -1.28% | 1,254,629 |
| 23/24/23 | 124.5 | +3.50% | 1,303,036 |
| 22/24/22 | 120.2 | +2.40% | 1,151,198 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
03/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.3
USD
Average target price
157.1
USD
Spread / Average Target
+28.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.18% | 19.47B | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- ILMN Stock
